DE60322509D1 - Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung - Google Patents

Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Info

Publication number
DE60322509D1
DE60322509D1 DE60322509T DE60322509T DE60322509D1 DE 60322509 D1 DE60322509 D1 DE 60322509D1 DE 60322509 T DE60322509 T DE 60322509T DE 60322509 T DE60322509 T DE 60322509T DE 60322509 D1 DE60322509 D1 DE 60322509D1
Authority
DE
Germany
Prior art keywords
igfbp
antisense oligonucleotides
bis
specific antisense
oligonucleotides inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322509T
Other languages
German (de)
English (en)
Inventor
Martin Gleave
Maxim Signaevsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60322509D1 publication Critical patent/DE60322509D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60322509T 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung Expired - Lifetime DE60322509D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
PCT/CA2003/000061 WO2003062421A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Publications (1)

Publication Number Publication Date
DE60322509D1 true DE60322509D1 (de) 2008-09-11

Family

ID=27613360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322509T Expired - Lifetime DE60322509D1 (de) 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Country Status (15)

Country Link
US (11) US20030158143A1 (enExample)
EP (1) EP1465995B1 (enExample)
JP (1) JP4491240B2 (enExample)
KR (2) KR101265180B1 (enExample)
AT (1) ATE402999T1 (enExample)
AU (1) AU2003237616B2 (enExample)
CA (1) CA2469685C (enExample)
DE (1) DE60322509D1 (enExample)
DK (1) DK1465995T3 (enExample)
ES (1) ES2307942T3 (enExample)
HU (1) HU229452B1 (enExample)
IL (2) IL162540A0 (enExample)
NO (1) NO333017B1 (enExample)
NZ (1) NZ533126A (enExample)
WO (1) WO2003062421A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR101265180B1 (ko) * 2002-01-17 2013-05-29 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
AU2003297259A1 (en) * 2002-11-14 2004-06-03 Wyeth Methods and compositions for treating neurological disorders
CA2539727C (en) 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
JP5376948B2 (ja) 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
SG10201601917XA (en) 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CA2844640A1 (en) * 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
KR102755601B1 (ko) * 2015-10-14 2025-01-17 바이오-패쓰 홀딩스 인크. 리포좀 제제를 위한 p-에톡시 핵산
FI3364993T3 (fi) 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
CA3053781A1 (en) 2017-02-15 2018-08-23 Cavion, Inc. Benzopyran and naphalene derivatives and their uses as calium channel inhibitors
IL269608B2 (en) 2017-04-19 2024-06-01 Bio Path Holdings Inc Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease
US12234457B2 (en) 2017-04-19 2025-02-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for BCL2 inhibition
CA3061720A1 (en) 2017-04-26 2018-11-01 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치
JP7480131B2 (ja) 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503949A (ja) 1990-08-28 1994-05-12 カイロン　コーポレイション 新規インシュリン様成長因子結合タンパク質ｉｇｆｂｐ―５
CA2090705A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995017507A1 (en) * 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
ES2221039T3 (es) * 1996-02-14 2004-12-16 Isis Pharmaceuticals, Inc. Oligonucleotidos abiertos modificados con azucar.
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
AU768904B2 (en) * 1999-06-21 2004-01-08 Murdoch Childrens Research Institute, The A method for the prophylaxis and/or treatment of medical disorders
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
EP1200579B1 (en) * 1999-07-19 2008-04-23 The University of British Columbia Antisense therapy for hormone-regulated tumors
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
WO2001046455A2 (en) 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
US7196067B2 (en) * 2000-09-14 2007-03-27 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
US6750019B2 (en) * 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
KR101265180B1 (ko) * 2002-01-17 2013-05-29 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물
CA2485589A1 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
PE20121495A1 (es) * 2009-07-30 2012-11-19 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta

Also Published As

Publication number Publication date
US7928082B2 (en) 2011-04-19
US8541390B2 (en) 2013-09-24
US8252765B2 (en) 2012-08-28
US20110196019A1 (en) 2011-08-11
NZ533126A (en) 2006-04-28
HU229452B1 (en) 2013-12-30
IL162540A (en) 2011-06-30
US20130096180A1 (en) 2013-04-18
NO333017B1 (no) 2013-02-18
CA2469685C (en) 2013-03-12
NO20043401L (no) 2004-10-13
ATE402999T1 (de) 2008-08-15
HUP0402543A3 (en) 2012-09-28
US20030158143A1 (en) 2003-08-21
IL162540A0 (en) 2005-11-20
US9101646B2 (en) 2015-08-11
AU2003237616B2 (en) 2007-07-05
US20120220646A1 (en) 2012-08-30
US8835401B2 (en) 2014-09-16
DK1465995T3 (da) 2008-10-20
US8470796B2 (en) 2013-06-25
CA2469685A1 (en) 2003-07-31
US8580761B2 (en) 2013-11-12
US20160002630A1 (en) 2016-01-07
WO2003062421A1 (en) 2003-07-31
EP1465995B1 (en) 2008-07-30
KR101265180B1 (ko) 2013-05-29
ES2307942T3 (es) 2008-12-01
US20060122141A1 (en) 2006-06-08
US20080261912A1 (en) 2008-10-23
US7973017B2 (en) 2011-07-05
US20100267808A1 (en) 2010-10-21
EP1465995A1 (en) 2004-10-13
JP4491240B2 (ja) 2010-06-30
KR101166214B1 (ko) 2012-07-16
JP2005514948A (ja) 2005-05-26
KR20040085150A (ko) 2004-10-07
US20110190382A1 (en) 2011-08-04
US20120077861A1 (en) 2012-03-29
KR20110026023A (ko) 2011-03-14
US8389491B2 (en) 2013-03-05
HUP0402543A2 (hu) 2005-03-29
US20130303592A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
ATE402999T1 (de) Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
DE60211937D1 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
IL197159A (en) Two-stranded rna molecules that complement a sense or antisense strand of a human encoding igfbp-2 and igfbp-5, preparations containing them and their uses
EP1412371A4 (en) PRODUCTION IN VIVO OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING
DE60317663D1 (de) Fluorchemische zusammensetzung enthaltend einen fluorierten polyether und dessen verwendung zur behandlung von fasermaterialien
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
HRP20070189A2 (en) Use of erythropoietin
ATE418336T1 (de) Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
PT1575951E (pt) Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
CA104143S (en) Brush
BR0313522A (pt) Uso de oligonucleotìdeos anti-sentido para inibir a expressão de akt-1
ATE518531T1 (de) Alpha-humulene zur verwendung bei der prophylaxe oder behandlung der entzündlichen schmerzen und des ödems
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
BG105779A (en) Human antibiotic proteins
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
EP1601325A4 (en) ANTI-SENSE OLIGONUCLEOTIDES INHIBITING EXPRESSION OF HIF-1
FI20020360A0 (fi) Biologisesti aktiivisen tuotteen uusi käyttö
EP1610807A4 (en) USE OF RECURRENT SEQUENCE PROTEIN POLYMERS IN PERSONAL CARE COMPOSITIONS
AU309683S (en) Massaging belt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition